Skip to main content
Press release November 9, 2026

Nanobiotix to Participate in Investor Conferences in November

Nanobiotix S.A. (NBTX)

PARIS and CAMBRIDGE, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in the following investor conferences in November: Jefferies Global Healthcare Conference in London Date: Monday, November 16, 2026 Presentation Time: 8:30am ET / 1:30pm GMT Location: London (UK) Presenters: Laurent Levy, Chief Executive Officer and Arnd Christ, Chief Financial Officer UBS Global Biopharma Conference Date: Tuesday, November 17, 2026 Location: London (UK) About NANOBIOTIX Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations. Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system. For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. Nanobiotix Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com Investor Relations Department Joanne Choi VP, Investor Relations (US) joanne.choi@nanobiotix.com Ricky Bhajun Director, Investor Relations (EU) +33 (0) 79 97 29 99 investors@nanobiotix.com Media Relations France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr Global – uncapped Becky Lauer +1 (646) 286-0057 uncappednanobiotix@uncappedcommunications.com PR-20261109-November_Conference_Participation_2026
View original release